357262-96-5

Basic information

• Product Name: Piperazine, 4-benzoyl-2-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxo acetyl]-, (2R)-
• CAS NO: 357262-96-5
• Molecular Formula: C21H19N5O6
• Molecular Weight: 437.412
• Mol File: 357262-96-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Piperazine, 4-benzoyl-2-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxo acetyl]-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 4-benzoyl-2-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxo acetyl]-, (2R)-(357262-96-5)
• EPA Substance Registry System: Piperazine, 4-benzoyl-2-methyl-1-[(4-nitro-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxo acetyl]-, (2R)-(357262-96-5)

Safety Data

• Hazardous Substances Data: 357262-96-5(Hazardous Substances Data)

Upstream product

• 357262-60-3 (R)-1-(4-benzoyl-2-methylpiperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridin-3-yl)ethane-1,2-dione 
• 357263-39-9 1-benzoyl-3-(R)-methylpiperazine 
• 357263-49-1 methyl α-oxo-1H-pyrrolo[2,3-b]pyridine-3-acetate 
• 271-63-6 7-Azaindole 
• 357262-90-9 4-benzoyl-2-(R)-methyl-1-[(7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]piperazine 
• 93-58-3 benzoic acid methyl ester 
• 75336-86-6 (2R)-methylpiperazine 

Downstream Products

• 357263-13-9 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 357263-05-9 4-benzoyl-1-[(4-methoxy-7-oxido-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine 
• 1430096-72-2 C₅₁H₆₄N₈O₁₄ 
• 1293397-32-6 C₂₉H₃₅N₇O₇ 
• 1196449-89-4 ARM-H 
• 1196449-88-3 C₃₃H₄₃N₇O₉ 

Relevant articles and documents

Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

Indole derivative 1 interferes with the interaction of the HIV surface protein gp120 with the host cell receptor CD4. The 4-fluoro derivative 2 exhibited markedly enhanced potency and was bioavailable in the rat, dog, and cynomolgus monkey when administered orally as a solution formulation. However, aqueous suspensions of 2 were poorly bioavailable, indicative of dissolution-limited absorption. The 7-azaindole derivative 3, BMS-378806, exhibited improved pharmaceutical properties while retaining the HIV-1 inhibitory profile of 2.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.